News
🇪🇺 EuropeLatest pharmaceutical news, drug approvals, and EMA regulatory updates
Breaking FDA Approves Auvelity for MDD: Axsome Therapeutics Scores Win
The U.S. Food and Drug Administration (FDA) has approved Auvelity, a novel oral antidepressant developed by Axsome Therapeutics, for the treatment of Major Depressive Disorder (MDD) in adults. This approval represents a significant advancement in the mental health landscape.
Latest News
EMEA 2026 Life Sciences Report: Key Market Shifts for Pharma BD and Investors
JLL's EMEA 2026 Life Sciences Industry & Cluster Report highlights strong public market performance, rising venture capital flows, and the transformative impact of AI on European life sciences clusters. The analysis provides actionable intelligence for pharma business development teams and investors navigating the evolving landscape.
Maersk Europe Market Update June 2026: Key Changes for Pharma Supply Chains
Maersk's June 2026 Europe market update details emergency bunker surcharges, war risk premiums, and ongoing port congestion. This analysis explains the implications for pharmaceutical supply chains, freight costs, and strategic planning.
Regulatory round-up: 2 February 2026 – EMA opinions, FDA approvals, and what they mean for pharma
The EMA's CHMP issued multiple positive opinions for new medicines and label extensions in late January, setting the stage for European launches. Meanwhile, FDA novel drug approvals continue to shape the 2026 pipeline. This round-up covers the key decisions and their commercial impact.
The Baker Company Benelux BV joins EuropaBio: Advancing cell culture and lab safety technologies
The Baker Company Benelux BV has joined EuropaBio, the European Association for Bioindustries, to advance cell culture and lab safety technologies. This membership signals a strategic push to align biosafety cabinet innovation with European biotech regulatory frameworks.
Myasthenia Gravis Clinical Trial Pipeline Expands as 25+ Companies Race to Redefine Myasthenia Gravis Treatment Landscape | DelveInsight — regulatory updates
DelveInsight’s latest pipeline report reveals over 25 companies developing 30+ therapies for myasthenia gravis, with FcRn blockers and CAR-T therapies leading innovation. The report highlights key regulatory updates, biomarker progress, and the emerging concept of MG 'age' and 'stage'.
MFN Drug Pricing Reshapes International Life Sciences Licensing Deals
The Most Favored Nation (MFN) drug pricing policy is fundamentally altering the landscape for international life sciences licensing deals. This analysis explores how MFN pricing introduces sustained downward pressure on U.S. list prices, reshapes valuation and diligence, and creates new strategic considerations for BD teams and investors.
India-Oman CEPA Fast-Tracks Drug Approvals, Cuts Export Barriers for Pharma
The India-Oman Comprehensive Economic Partnership Agreement (CEPA) entered into force on June 1, 2026, granting Indian pharmaceutical exports zero-duty access on 98% of tariff lines and a 90-day fast-track approval pathway for drugs already approved by the USFDA, EMA, UK MHRA, or TGA. The deal also includes mutual recognition of GMP standards and simplified compliance procedures, significantly reducing market access barriers for Indian drugmakers.
EMA, AMA and African Regulators Unite to Accelerate Ebola Clinical Trials
EMA's Emergency Task Force is engaging with the African Medicines Agency and its national regulatory authorities to discuss clinical trial designs and medical countermeasures for the ongoing Ebola outbreak caused by the Bundibugyo virus in DRC and Uganda.
WHO/Europe Initiative on Access to Novel Medicines: Market Implications for Pharma
WHO/Europe will convene a pivotal meeting on June 10, 2026, to address access to novel medicines, signaling a shift in pricing and reimbursement frameworks across the region. This article provides key takeaways, regulatory context, and actionable implications for pharmaceutical business development and investment teams.
Hayes Receives 2026 ESMO Breast Cancer Award: Key Insights
Daniel F. Hayes, M.D., has been awarded the 2026 ESMO Breast Cancer Award, recognizing his transformative contributions to breast cancer research. This article provides key takeaways, regulatory context, and implications for pharma business development and investment teams.
Owkin and AstraZeneca Enhance AI Collaboration for Drug Research
Owkin and AstraZeneca have expanded their collaboration to develop AI-driven drug research tools, aiming to accelerate clinical trials and reduce costs. This deal intelligence article provides key takeaways, regulatory implications, and an FAQ section for pharma teams and investors.
Cancer Therapy OST-HER2 Faces 2026 EMA Call After Survival Data
OST-HER2, a novel cancer therapy, is set for a 2026 EMA review following promising survival data. This article covers key takeaways, regulatory details, and strategic implications for pharma teams and investors.
EU Commission Advances Critical Medicines Act: Market Implications
The EU Commission has formally advanced the Critical Medicines Act, a legislative package aimed at securing supply chains for essential drugs. This article outlines key takeaways, regulatory implications, and strategic considerations for pharma business development teams and investors.
Insights from ESMO Asia: Nadia Harbeck on Oncology Advances
Nadia Harbeck's presentation at ESMO Asia 2025 underscores the accelerating shift toward precision oncology, with implications for biomarker-driven R&D and regulatory strategy. This article expands on her insights with key takeaways, regulatory context, and a FAQ section for pharma decision-makers.
CHMP May 2026 Output: A New Era in Drug Approvals
The CHMP May 2026 output marks a structural shift in European drug approvals, with implications for pharma BD teams, investors, and analysts. This article covers key takeaways, the development with dates and sources, and FAQs based on EMA guidance.
CHMP Negative Opinion on Acadia's Rett Syndrome Drug: Implications for Investors and Pharma Teams
The European Medicines Agency's CHMP has adopted a negative opinion on Acadia Pharmaceuticals' trofinetide (Daybue) for Rett syndrome, citing concerns from the pivotal Lavender trial. This decision impacts Acadia's European market strategy and raises questions for pharma teams developing rare disease therapies.
Biosimilar Approvals: U.S. vs. Europe Insights for Pharma BD
Explore the diverging landscapes of biosimilar approvals in the U.S. and Europe. This analysis offers critical insights for pharmaceutical business development teams, investors, and analysts navigating market entry strategies.
Key Cancer Drugs to Watch at ESMO 2025: Investor and BD Insights
ESMO 2025 is poised to unveil critical data on next-generation cancer therapies. This article highlights key drugs and their implications for pharmaceutical business development, investment strategies, and the evolving oncology landscape.
European Navenibart Deal: A Strategic Win for BioCryst's Rare Disease Portfolio
BioCryst Pharmaceuticals has secured a significant European deal for its rare disease drug, Navenibart, bolstering its portfolio and reaffirming its 2026 financial outlook. This strategic move positions the company for expanded market presence and potential revenue growth.
EMA Horizon Scanning: Navigating Regulatory Updates for Future Medicines
The European Medicines Agency (EMA) is proactively engaging in horizon scanning to anticipate future medicines and technological advancements. This strategic foresight aims to ensure regulatory preparedness and resilience within the European medicines regulatory system, impacting pharmaceutical R&D and market strategies.